Session 2: Treatment of HHT

08 Jun 2017
10:30 am - 12:30 pm
Soderini Ballroom II, III

Session 2: Treatment of HHT

Invited Speaker:  Dr. Luca Jovine  (10:30am – 11:15am)

What the Human Endoglin-BMP9 Complex Looks Like and What Does It Tell Us

 

Oral Presentations

11:15am – 11:30am

Effect of systemic bevacizumab on invasive cardiac hemodynamics among patients with hereditary hemorrhagic telangiectasia and high output heart failure.

Allred C, Johnson K, Whitehead K

 

11:30am – 11:45am

Intravenous bevacizumab for the management of transfusion dependent blood-loss anemia in hereditary hemorrhagic telangiectasia

A standardized treatment protocol of Intravenous Bevacizumab for refractory HHT related epistaxis and gastrointestinal bleeding

Iyer V, Apala D, Pannu B, Kotecha A, Brinjikji W, Leise M, Kamath P, Misra S, Begna K, Cartin-Ceba R, Pruthi R, DuBrock H, Krowka M, Swanson K

 

11:45am – 12:00pm

Dietary assessments suggest many patients with hereditary hemorrhagic telangiectasia do not ingest recommended dietary allowance (RDA) for iron, and may spontaneously modify their diet to avoid nosebleed precipitants

Finnamore H, Hickson M, Whelan K, Shovlin C

 

12:00pm – 12:15pm

Long term follow-up of hereditary haemorrhagic telangiectasia patients who underwent liver transplantation for severe liver involvement

Boillot O, Dupuis-Girod S, Faure F, Ginon I, Saurin JC, Guillaud O, Dumortier J

 

12:15pm – 12:30pm

Metafore study: 8 years later. Follow-up of HHT patients treated with bevacizumab for severe hepatic vascular malformations and high cardiac output

Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Carette MF, Gilbert-Dussardier B, Hatron PY, Pascal Lacombe, Chinet T, Leguy-Seguin V, Rivière S, Corre R, Giraud S, Fargeton AE, Bailly S, Paintaud G, Valette PJ, Faure F